about
The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan.In vitro antifungal activity and cytotoxicity of a novel membrane-active peptideStrong antifungal activity of SS750, a new triazole derivative, is based on its selective binding affinity to cytochrome P450 of fungi.Antifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profileMultilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.Colonization of human immunodeficiency virus-infected outpatients in Taiwan with Candida speciesExperimental induction of fluconazole resistance in Candida tropicalis ATCC 750Canadian clinical practice guidelines for invasive candidiasis in adults.Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testingOverexpression of Both ERG11 and ABC2 Genes Might Be Responsible for Itraconazole Resistance in Clinical Isolates of Candida krusei.Upregulation of the ERG11 gene in Candida krusei by azolesAbc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.Efflux-mediated antifungal drug resistance.Identification of Candida species in patients with oral lesion undergoing chemotherapy along with minimum inhibitory concentration to fluconazoleBlood stream infections by Candida glabrata and Candida krusei: a single-center experienceUnderstanding the Antifungal Mechanism of Ag@ZnO Core-shell Nanocomposites against Candida krusei.Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species.Conventional and alternative antifungal therapies to oral candidiasis.Evaluation of the new Micronaut-Candida system compared to the API ID32C method for yeast identification.Whole Genome Sequence of the Heterozygous Clinical Isolate Candida krusei 81-B-5.Fluconazole resistance in Candida species: a current perspective.Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei.Restriction enzyme analysis of ribosomal DNA shows that Candida inconspicua clinical isolates can be misidentified as Candida norvegensis with traditional diagnostic procedures.Activity of fluconazole and its Cu(II) complex towards Candida species.Overexpression of MDR-1 and CDR-2 genes in fluconazole resistance of Candida albicans isolated from patients with vulvovaginal candidiasis.Antidermatophytic Activity of the Fruticose Lichen Usnea orientalis.In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei.Antifungal amphiphilic kanamycins: new life for an old drugMicrobiological screening of Irish patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy reveals persistence of Candida albicans strains, gradual reduction in susceptibility to azoles, and incidences of clinical signs of oral cResponding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside
P2860
Q24814052-4FFC163D-ED2B-4539-A15E-1D175B86D3D9Q28343417-B0BD7336-3780-4995-AE6A-8DBC126E919AQ28345157-152E6062-2225-4683-8674-F99EE07C08DDQ28489096-8D2D9DB1-FEC4-48ED-84EE-1819D881E8BEQ33622915-EDF332B7-4980-4A0C-8444-4325E7041FA2Q33749111-ADAB5628-72B5-4518-A3E1-6A4DFE8B2558Q33753327-33E177CC-50B9-45A5-80DE-4028D067FD60Q33979724-D56DD99B-65FF-45DC-97F6-237073C76C5CQ34237335-9483E604-7288-4CEB-AE86-0C02604A5763Q34647337-92F1DE42-D677-412A-81B9-C2A3E3154ACCQ35756098-46159FF4-F2D4-4D90-B8F2-2626DB5EB21EQ35832184-34EE2413-D159-408D-BB4F-085D3797E79BQ37072109-2AA952FF-9F04-4FD9-A6C8-3603EC8D5C28Q37156645-F6A40387-E4F7-4C1E-9758-7AFF853BB2A0Q37261224-A2911579-C60C-48FA-B0FE-1B8E0C7F26DEQ37320979-DCEFA84B-527F-4683-9DD7-E51105B8F728Q37393878-531DC90E-8237-48D1-97D1-B10E8BE23B6CQ37580801-E8ECCB4B-FCAB-4C7C-BC67-D676FBDE19A5Q38137060-6508F1D6-3998-44A7-9BF3-3E42F93D6BDBQ38609418-E82F307A-AFA1-4B3F-AF06-98D6751666D5Q38684199-4CF7AEB2-9210-4302-9320-5612AAA2A404Q39092120-35383CFE-D142-4EFB-85C6-A910736B6937Q39743425-534A7971-2B68-45DB-BB87-E504FFB578BCQ40172874-775FCE7D-A191-4DBF-AE40-D6C53C7C95D3Q40673716-73A4EBE7-B75E-4B49-AFFB-9087F0856D18Q41671656-284267C8-3A28-4DDF-858A-9882D3342E8CQ41747804-E1A78205-D11A-4EBC-8D2E-717262F6CC1DQ42109755-13F42DB5-EE00-49AD-BCE1-E1EE45938974Q57103893-E620E787-173E-44BA-ADEF-000F58C0B65BQ58490188-EE6D49CC-B434-47B0-9F85-9EFBAC6B52E8Q58772251-23B4F41B-64FF-4448-A1C4-4AEBE1BCD6C9
P2860
description
1998 nî lūn-bûn
@nan
1998 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Mechanism of fluconazole resistance in Candida krusei.
@ast
Mechanism of fluconazole resistance in Candida krusei.
@en
type
label
Mechanism of fluconazole resistance in Candida krusei.
@ast
Mechanism of fluconazole resistance in Candida krusei.
@en
prefLabel
Mechanism of fluconazole resistance in Candida krusei.
@ast
Mechanism of fluconazole resistance in Candida krusei.
@en
P2093
P2860
P1476
Mechanism of fluconazole resistance in Candida krusei.
@en
P2093
A S Ibrahim
A S Orozco
C A Hitchcock
D Falconer
L M Higginbotham
M A Ghannoum
S G Filler
T Parkinson
P2860
P304
P407
P577
1998-10-01T00:00:00Z